Below are the highlights from the conference call. We remind that Akzo's 4Q adjusted EBITDA increased by 3% and came in c. 2% below our forecast and c. 1% below consensus, with a better than expected result of Performance Coatings offset by a weaker result of Deco Paints. Net debt/EBITDA came in weaker than expected at 3x on the back of incidentals and higher than expected working capital. FY25 adj EBITDA guidance calls for at least 5% growth which is in line with our forecast with consensus at ...
Rdos. 4T'24 vs 4T'23: Ventas: 9.263 M euros (+28,0% vs +24,0% BS(e) y +24,8% consenso); EBIT: 3.355 M euros (+40,3% vs +27,6% BS(e) y +28,6% consenso); BDI: 2.693 M euros (+31,5% vs +27,3% BS(e) y +28,2% consenso). Rdos. 2024 vs 2023: Ventas: 28.263 M euros (+2,6% vs +1,5% BS(e) y +1,7% consenso); EBIT: 9.022 M euros (-0,2% vs -3,6% BS(e) y -3,3% consenso); BDI: 7.572 M euros (-3,4% vs -4,5% BS(e) y -4,3% consenso).
Akzo's 4Q adjusted EBITDA increased by 3% and came in c. 2% below our forecast and c. 1% below consensus, with a better than expected result of Performance Coatings offset by a weaker result of Deco Paints. FY25 adj EBITDA guidance calls for at least 5% growth which is in line with our forecast with consensus at +7%, whilst most of the predicted growth comes from self-help measures. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 70 TP.
ASML's 4Q24 results exceed expectations. Order intake was € 7.1bn, twice the street's expectations of € 3.5bn. ASML reported €9.3bn in revenues for 4Q24, surpassing both guidance and expectations (KBCS & CSS: € 9.0bn) due to a strong performance of IBM. Higher IBM revenues combined with lower than expected costs, related to the sale of two high NA tools, resulted in better than expected margins. Consequently, EPS of € 6.85 exceeded the street's expectations of € 6.68 (KBCS: € 6.61). The outlook ...
Onward's ARC-EX system is now available on two federal procurement platforms, including the US Veterans Affairs (VA) and General Services Administration (GSA) Advantage, allowing US government clinics to purchase the system. The inclusion was facilitated by Onward's existing partnership with Lovell. The company remains on track in its commercial launch for the ARC-EX device, hence we reiterate our € 10.4 TP and Buy rating.
COMPAÑÍAS QUE APARECEN EN EL INFORME: EUROPA: ASML, LVMH. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’24 que se publicarán en España y Europa en los próximos días. Recuperación del mercado Rebote en Europa ayudado por la recuperación de las grandes empresas estadounidenses (las FANGS subían un +5,1% al cierre de Europa). En el STOXX 600 lideraron...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.